

Thomas Glanzmann becomes non-executive Chairman to focus solely on Board responsibilities

- *Glanzmann, named Executive Chairman in February 2023, will now fully dedicate his time to the non-executive Chairmanship role*
- *Only CEO Nacho Abia will have executive functions for the company, a change that follows a swift and successful transition*
- *The move further strengthens the company's corporate governance, marking a clear separation between the Board and the daily management of Grifols, and concludes a long-term transition plan*

Barcelona, Spain, Sept. 23, 2024 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that Thomas Glanzmann will become non-executive Chairman of the Board of Directors, and that CEO Nacho Abia will assume all executive responsibilities.

The change was approved by the Board and is effective immediately. It is the final step of a long-term management transition plan initiated in 2022.

Glanzmann, appointed Executive Chairman in February 2023, will now fully dedicate his time, energy and experience to the non-executive Chairmanship role, overseeing and protecting the interests of all Grifols stakeholders.

Accelerating the change, initially foreseen to happen in February 2025, is the result of a well-planned and successful transition and reflects the Board's confidence in Abia, who assumed the CEO role on April 1, 2024. Since then, Abia has taken firm management control of the businesses, streamlined decision making and enhanced operational excellence. Abia will continue to prioritize business growth, further debt reduction and ongoing improvements to the company's free cash flow.

Glanzmann focusing solely on the Board as non-executive Chairman further strengthens the company's corporate governance, providing additional separation between the Board and day-to-day management of Grifols. No other changes are expected to the 11-member Board, on which Montserrat Muñoz will continue as the Independent Lead Director.

"It is and truly has been a privilege and an honor to serve as Executive Chairman for an amazing company such as Grifols and be part of its significant transformation at a time of great progress as well as unmerited challenges," Glanzmann said. "Grifols today is well-positioned for the future, and I believe that now I can best serve this 115-year-old company as its non-executive Chairman. Starting today I will devote all my energies and focus to the

GRIFOLS

Board and its responsibilities ensuring that we are making the right decisions in the best interests of all Grifols stakeholders.

“I thank all the extraordinary Grifols team members, who continue giving their best for patients and customers, especially at the most challenging moments,” he added. “I have great confidence and trust in Nacho Abia, who in a short time has proven to be a first-class executive with the talent and vision to lead this company into the future. In my new role I very much look forward to continuing to support and work with him, the leadership and the entire Grifols team to successfully write the next chapter in the company’s long history as an industry innovator and leader.”

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – +34 91 311 92 90

Raquel Lumbreras (Tel. +34 659 572 185)

Raquel_lumbreras@duomocomunicacion.com

Borja Gómez (Tel. + 34 659 572 185)

Borja_gomez@duomocomunicacion.com

Investors

Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

Tel. +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

GRIFOLS

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.